PIK3CA and sarcopenia: In the current study, results of bioinformatics analysis and network pharmacology analysis showed that main active components of MC target the core proteins of PI3K-Akt signaling pathway, EGFR tyrosine kinase inhibitor resistance, longevity regulating pathway, which may play a certain therapeutic role in sarcopenia.